/BMYMP
BMYMP Stock - Bristol-Myers Squibb Company PFD CONV 2
Healthcare|Drug Manufacturers - GeneralOTC
$910.00+0.00%
+$0.00 (+0.00%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1001.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BMYMP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$900.90 – $919.10
TARGET (TP)$1046.50
STOP LOSS$837.20
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$1065.75
52W Low$720.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B |
| Gross Profit | $27.43B | $25.36B | $26.49B | $26.76B | $21.70B |
| Gross Margin | 56.8% | 56.3% | 57.4% | 57.7% | 51.0% |
| Operating Income | $9.66B | $8.47B | $9.27B | $9.54B | $4.49B |
| Net Income | $-8,948,000,000 | $8.03B | $6.33B | $6.99B | $-8,995,000,000 |
| Net Margin | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% |
| EPS | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.98 |
Company Overview
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BMYMPBeat Rate
100%
Last 3 quarters
Avg Surprise
+1038.8%
EPS vs Estimate
Beats / Misses
3/0
Last 12 quarters
Latest EPS
$17.99
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
+1150.3%
$18.63vs$1.49
Q3 25
+882.6%
$10.71vs$1.09
Q4 25
+1083.6%
$17.99vs$1.52
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Oct 29, 2026 | — | — | — | — |
Q3 2026 | Jul 30, 2026 | — | — | — | — |
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $1.52 | $17.99 | +1083.6% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $1.09 | $10.71 | +882.6% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $1.49 | $18.63 | +1150.3% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | — | $0.55 | — | — |
Q4 2024 | Oct 31, 2024 | — | $9.17 | — | — |
Q3 2024 | Jul 26, 2024 | — | $12.74 | — | — |
Q2 2024 | Apr 25, 2024 | — | $-90.58 | — | — |
Q1 2024 | Mar 4, 2024 | — | $13.33 | — | — |
Q1 2024 | Jan 8, 2024 | — | $14.37 | — | — |
Q3 2023 | Jul 27, 2023 | — | $15.17 | — | — |
Q2 2023 | Apr 27, 2023 | — | $16.47 | — | — |
Q1 2023 | Feb 14, 2023 | — | $14.65 | — | — |
Q4 2022 | Oct 26, 2022 | — | $15.07 | — | — |
Q3 2022 | Jul 27, 2022 | — | $13.33 | — | — |
Q2 2022 | Apr 29, 2022 | — | $11.99 | — | — |
Q1 2022 | Feb 9, 2022 | — | $22.25 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BMYMP
What is BMYMP's current stock price?
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is currently trading at $910.00 per share. The stock has moved +0.00% today.
What is the analyst price target for BMYMP?
No analyst price targets are currently available for this stock.
What sector is Bristol-Myers Squibb Company PFD CONV 2 in?
Bristol-Myers Squibb Company PFD CONV 2 operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.
What is BMYMP's market cap?
Bristol-Myers Squibb Company PFD CONV 2 has a market capitalization of $1852.53 billion, making it a mega-cap company.
Does BMYMP pay dividends?
No, Bristol-Myers Squibb Company PFD CONV 2 does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZNCF
AstraZeneca PLC
$181.23
Mkt Cap: $281.0B
BAYRY
Bayer AG
$10.45
Mkt Cap: $41.1B
CHGCF
Chugai Pharmaceutical Co., Ltd.
$52.65
Mkt Cap: $86.6B
CHGCY
Chugai Pharmaceutical Co., Ltd.
$26.49
Mkt Cap: $87.2B
GLAXF
GSK plc
$24.03
Mkt Cap: $96.8B
NVSEF
Novartis AG
$129.60
Mkt Cap: $248.7B
RHHBF
Roche Holding AG
$409.77
Mkt Cap: $326.3B
RHHBY
Roche Holding AG
$51.20
Mkt Cap: $326.2B
RHHVF
Roche Holding AG
$416.11
Mkt Cap: $331.4B
SNYNF
Sanofi
$95.90
Mkt Cap: $116.8B
Explore stocks similar to BMYMP for comparison